Effects of granulocyte-colony-stimulating factor on mobilization of bone-marrow-derived stem cells after myocardial infarction in humans

被引：21

作者：

Nienaber C.A. ^{[1
]}

Petzsch M. ^{[1
]}

Kleine H.D. ^{[2
]}

Eckard H. ^{[1
]}

Freund M. ^{[2
]}

Ince H. ^{[1
]}

机构：

[1] Department of Cardiology, Rostock University Hospital, Rostock School of Medicine, 18057 Rostock

[2] Department of Hematology, Rostock University Hospital, Rostock School of Medicine, 18057 Rostock

来源：

Nature Clinical Practice Cardiovascular Medicine | 2006年 / 3卷 / Suppl 1期

关键词：

Cytokines; G-CSF; Mobilizattion; Myocardial infarction; Stem cells;

D O I：

10.1038/ncpcardio0443

中图分类号：

学科分类号：

摘要：

Recent experimental studies have shown that granulocyte-colony-stimulating factor (G-CSF) enhanced cardiac function after infarction. The concept of direct cytokine or cell-mediated effects on postischemic myocardial function was tested in the setting of human myocardial infarction subjected to percutaneous coronary intervention. In the FIRSTLINE-AMI study 50 consecutive patients with first ST-elevation myocardial infarction were randomly assigned to receive either 10 μg/kg G-CSF for 6 days after percutaneous coronary intervention in addition to standard medication, or standard care alone. G-CSF administration led to mobilization of CD34+ mononuclear stem cells (MNCCD34+), with a 20-fold increase to 64 ±37 MNCCD34+/μl at day 6 without significant associated changes in rheology, blood viscosity or inflammatory reaction, or any major adverse effects. At 4 months the G-CSF group showed improved left ventricular ejection fraction of 54 ± 8% versus 48 ± 4% at baseline (P <0.001), and no evidence of left ventricular end-diastolic remodeling, with a diameter of 55 ± 5 mm and improved segmental wall thickening (P<0.001); conversely, in control patients left ventricular ejection fraction was 43 ± 5% at 4 months (P<0.001), with increased left ventricular end-diastolic dimension of 58 ± 4 mm (P<0.001), and no segmental wall thickening. In conclusion, the FIRSTLINE-AMI study showed that G-CSF administration and mobilization of MNCCD34+ after reperfusion of infarcted myocardium may offer a pragmatic strategy for preservation of human myocardium and prevention of remodeling without evidence of aggravated atherosclerosis. © 2006 Nature Publishing Group.

引用

页码：S73 / S77

页数：4

共 23 条

[11] Frangogiannis N.G., Et al., The inflammatory response in myocardial infarction, Cardiovasc Res, 53, pp. 31-47, (2002)
[12] Frangogiannis N.G., Et al., MCSF expression is induced in healing myocardial infarcts and may regulate monocyte and endothelial cell phenotype, Am J Physiol, 285, pp. 483-492, (2003)
[13] Massa M., Et al., Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction, Blood, 105, pp. 199-205, (2005)
[14] Kajstura J., Et al., Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion, Circ Res, 96, pp. 127-137, (2005)
[15] Murry C.E., Et al., Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts, Nature, 428, pp. 664-668, (2004)
[16] Balsam L.B., Et al., Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium, Nature, 428, pp. 668-673, (2004)
[17] Kocher A.A., Et al., Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function, Nat Med, 7, pp. 430-436, (2001)
[18] Wojakowski W., Et al., Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction, Circulation, 110, pp. 3213-3220, (2004)
[19] Vulliet P.R., Et al., Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs, Lancet, 363, pp. 783-784, (2004)
[20] Balagner H., Et al., Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor, Transfusion, 44, pp. 1260-1261, (2004)

← 1 2 3 →